Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets.
Sign up today and learn more about Exicure Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Exicure Stock
David A. Giljohann
Chad A. Mirkin
C. Shad Thaxton
Director Program Management